Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Pretrial of Daunorubicin Cytarabine Liposome in Older, Naive AML
NCT04920500Unknown
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoint: Pharmacokinetics of Daunorubicin Cytarabine liposomes up to 12 days. Status: unknown.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04920500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920500.